Mandate

Vinge advises Industrifonden and SEB in connection with Clavister investment

April 16, 2012

Vinge has advised Industrifonden and SEB Venture Capital in connection with their approximately SEK 40 million investment in the security company Clavister AB. The company, which has its registered office in Örnsköldsvik, offers advanced security products focusing on the telecoms industry, cloud computing environments and large corporate customers. The capital will be used for the company’s future international expansion.

SEB Venture Capital was founded in 1995 and is part of the SEB group. With a capital base of SEK 2 500 million, the company has thus far made 36 investments in technology and healthcare enterprises and performed 36 exits. Read more about SEB Venture Capital by visiting www.seb.se/venturecapital

Industrifonden has assets worth SEK 3.8 billion and investments in 89 companies within the technology, cleantech, life science and industrial sectors. This is Industrfonden’s seventh new investment for the financial year comprising 1 July 2011 to 30 June 2012. Read more about Industrifonden by visiting www.industrifonden.se

Vinge’e team consisted of partner Johan Larsson together with associates Philip Watson and Martin Hall.     

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024